ClinicalTrials.gg
Active, not recruitingNCT07719439Updated Jul 22, 2026

Heart Rate Variability and Early Cytokine Profile in Pediatric Adenotonsillectomy

An observational study in Heart Rate Monitoring, Vagal Bradycardia and Adenotonsillar Hypertrophy, sponsored by Duzce University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 5 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Duzce University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
76
Ages
5 Years to 9 Years
Sex
All
01

Study summary

This prospective observational cohort study will assess whether perioperative short-term heart rate variability (HRV) indices and early inflammatory cytokine levels are associated with respiratory and cardiac adverse events in children undergoing elective adenoidectomy, tonsillectomy, or adenotonsillectomy under general anesthesia. HRV will be recorded noninvasively from 30 minutes before surgery until discharge from the post-anesthesia care unit. Serum cytokines will be measured from 3 mL of residual blood obtained after induction of anesthesia. The study aims to identify perioperative physiologic markers associated with a lower or higher risk of adverse events, thereby supporting safer anesthetic planning.

Read the detailed description

Eligible children aged 5 to 9 years with ASA physical status I-II who are scheduled for elective adenoidectomy, tonsillectomy, or adenotonsillectomy will be enrolled consecutively after parental written informed consent. Standard clinical care will not be altered. HRV will be obtained using Holter/ECG monitoring and analyzed using time-domain (SDNN, RMSSD) and frequency-domain (LF, HF, LF/HF) measures. Standard intraoperative monitoring, Bispectral Index, and routine anesthetic management will be recorded. A residual 3 mL venous blood specimen collected at 5 minutes after intubation and before incision will be processed for IL-6, IL-8, IL-1, IL-1 beta, TNF-alpha, and IL-10 by ELISA. Postoperative emergence delirium will be evaluated with the Pediatric Anesthesia Emergence Delirium scale. Perioperative respiratory and cardiac adverse events will be prospectively documented until discharge from the PACU.

02

Conditions studied

  • Heart Rate Monitoring
  • Vagal Bradycardia
  • Adenotonsillar Hypertrophy
  • Tonsillitis; Hypertrophic
  • Adverse Cardiac Event
  • Respiratory Complication
  • Anesthesia
03

In context

Tonsillitis

103 studies on the registry are indexed under Tonsillitis; 12 are open to participants now.

This study's planned enrollment of 76 is below the median of 100 across 15 observational studies indexed under Tonsillitis.

Browse Tonsillitis studies →

Lead sponsor

Duzce University is the lead sponsor of 76 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

5-9 years, elective adenoidectomy, tonsillectomy, or adenotonsillectomy operation

  • ASA physical status I-II;
  • Surgery planned under general anesthesia;

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5-9 years;
  • elective adenoidectomy, tonsillectomy, or adenotonsillectomy operation
  • I-II;
  • surgery planned under general anesthesia;
  • able to undergo standard endotracheal intubation and standard anesthetic protocol

    -; no dermatologic or cardiac barrier to preoperative Holter monitoring;

  • written provided by parent/legal guardian.

Exclusion criteria

Exclusion Criteria:

  • III or higher; congenital heart disease, arrhythmia, or cardiac conduction disorder;
  • known neurologic disease (e.g., epilepsy or cerebral palsy);
  • psychiatric diagnosis;
  • chronic inflammatory or immune-system disease;
  • acute infection within 2 weeks before surgery
  • regular , , or anti-inflammatory medication use;
  • endocrine disease such as uncontrolled thyroid disease;
  • preoperative hemodynamic instability;
  • major unexpected intraoperative complication or ICU requirement;
  • intraoperative atropine, lidocaine, beta-blocker, or epinephrine use;
  • history of prematurity or syndromic disease;
  • parent/legal guardian declines consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
76 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. HRV parameters' effect on perioperative cardiac events

    Association between perioperative HRV parameters and perioperative respiratory/cardiac adverse events. HRV measures: SDNN, RMSSD, LF, HF, and LF/HF derived from Holter/ECG recordings. Adverse events include laryngospasm, bronchospasm, apnea/hypopnea, breath-holding, hypoxemia/desaturation, stridor, severe cough, and clinically relevant cardiac events. Time Frame: From 30 minutes before surgery until discharge from the PACU, up to 1 day.

    Time frame: 1 day. Until discharge from the PACU (same day)

Secondary outcomes

  1. Association between early serum cytokine concentrations (IL-6, IL-8, IL-1beta, TNF-alpha, IL-10) and perioperative respiratory/cardiac adverse events

    Association between early serum cytokine concentrations (IL-6, IL-8, IL-1beta, TNF-alpha, IL-10) and perioperative respiratory/cardiac adverse events. Time Frame: Blood sampling at 5 minutes after intubation and before incision; adverse-event assessment until PACU discharge, up to 1 day.

    Time frame: 1 day

  2. Association of HRV and PAED score after extubation

    Postoperative emergence quality assessed by the Pediatric Anesthesia Emergence Delirium (PAED) score. Time Frame: First 30 minutes after extubation in the PACU.

    Time frame: 30 minute after extubation

  3. Relationship of COLDS score and perioperative adverse events

    Relationship of COLDS score, Bispectral Index values, demographic/operative variables, and anesthetic exposure with perioperative adverse events. Time Frame: Preoperative assessment through PACU discharge, up to 1 day.

    Time frame: 30 minutes

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719439
Lead sponsor
Duzce University
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Jul 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 22, 2026

Study contacts

Sultan Baran Erkul, PhD
principal investigator · Duzce University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion